

Exhibit C

Additional Deposition Excerpts

Narendrakumar Patel
Deposition October 20, 2009

Page 129

Q. Did you have any knowledge
16 of any lab analyst who did not accurately
17 write the information in the lab notebook
18 from the TotalChrom or TurboChrom
19 printout?
20 MR. ANDERTON: Objection.
21 I'm going to ask that you phrase
22 your question relating
23 specifically to digoxin.

Page 130/131

MR. ANDERTON: I'm going to
11 ask you to listen to the question
12 and I'm going to instruct you to
13 answer only with respect to
14 digoxin.
15 THE WITNESS: Okay.
16 BY MR. MILLER:
17 Q. Are you aware for any
18 product that was being produced by
19 Actavis, of lab analysts not accurately
20 writing in a lab notebook what's
21 reflected on the results from TotalChrom
22 or TurboChrom?
23 MR. ANDERTON: Again, I'm
24 going to object and you may answer
1 the question, but only as concerns
2 knowledge about digoxin.

8 BY MR. MILLER:

9 Q. Next sentence: "Instances
10 were found where analysts aborted and
11 failed to complete chromatographic
12 testing runs after an out-of-specification
13 test result was obtained."
14 On digoxin or any product at
15 Actavis, were you aware this was taking
16 place?
17 MR. ANDERTON: Objection.
18 You may answer the question but
19 only with respect to digoxin.

Page 138

Q. I'm going to read paragraph
6 3, sir, if you're there. "There was a
7 failure to check for accuracy the inputs
8 to and outputs from the 'Total Chrom Data
9 Acquisition System,' which is used to run
10 your firm's HPLC instruments during
11 analysis of drug products."
12 Are you aware of this
13 happening for digoxin or any product at
14 Actavis Totowa?
15 MR. ANDERTON: Objection.
16 I'm going to instruct you to
17 answer the question only with
18 respect to digoxin.

Eamonn Murphy
Deposition October 21, 2009

Page 89/90

5 Q. Have you ever gotten any
6 written letter that was put in your
7 personnel file that outlined any failing
8 of either yourself or your quality
9 control group for any reason?
10 MR. ANDERTON: Objection.
11 I'm going to instruct the witness
12 to answer that only with respect
13 to yourself.
14 THE WITNESS: Can you ask me
15 the question again, please?
16 BY MR. THOMPSON:
17 Q. Have you ever gotten a
18 reprimand that was included in your
19 personnel file for any fault or problem
20 that you had at work or that your quality
21 control group had?
22 MR. ANDERTON: And, again,
23 I'm going to instruct you to
24 answer only with respect to
1 yourself.
2 THE WITNESS: With respect
3 to myself, no.
4 BY MR. THOMPSON:
5 Q. How about with respect to

6 the quality control group as a whole?

7 MR. ANDERTON: Objection.

8 I'm going to instruct the witness

9 not to answer.

Kwame Adjei

October 26, 2009

Page 75/76

4 Q As a lab analyst, have you ever made

5 an error accidentally or any other way when

6 transcribing data from a printout such as

7 Empower into your lab notebook?

8 MR. ANDERTON: Objection. I'm

9 going to instruct the witness to answer

10 only with respect to digoxin.

Page 90/91/92/93

9 Q Okay. Did you do any testing on

10 hydroxyzine?

11 MR. ANDERTON: Objection. I'm

12 going to instruct the witness not to

13 answer.

14 THE WITNESS: I don't remember.

15 MR. BLIZZARD: Let me just make

16 sure I'm clear on this. We're doing

17 discovery here. Are you -- and you're

18 instructing a witness not to answer a

19 question that I'm asking in the discovery

20 period of the case?

21 MR. ANDERTON: We have -- I'm

22 sure you're familiar, Ed, with PTO27,

23 which sets the scope of allowable

24 discovery in this case and limits

1 discovery to digoxin and digoxin-related

2 activities except with respect to

3 specific information laid out in PTO27.

4 MR. BLIZZARD: I'm not talking

5 about specific testing about another

6 product.

7 MR. ANDERTON: You asked --

8 MR. BLIZZARD: I'm asking him

9 about whether or not he's familiar with a

10 specific product. And this is background

11 information for the purposes of

12 discovery. And if you're going to
13 instruct him -- typically, the cases I'm
14 involved in, there's only instructions
15 not to answer when there's a privilege
16 issue. But you've been consistently
17 instructing witnesses not to answer on
18 discovery matters. From my
19 understanding, this is not in violation
20 of the current PTO, so that's why I'm
21 asking the question.

22 MR. ANDERTON: Well, first of
23 all, your question was not limited to
24 whether he had knowledge of a specific
1 product. You asked him, and the record
2 will show, expressly whether he tested
3 that product.

4 MR. BLIZZARD: Yes, I am.

5 MR. ANDERTON: That is --

6 MR. BLIZZARD: That was his
7 job.

8 MR. ANDERTON: That is a
9 direct -- that is directly outside the
10 scope of PTO27. The rule explicitly
11 permits instruction to a witness not to
12 answer to enforce the terms of a court
13 order. We have that order. It's PTO27.
14 It speaks to the non-Digitek information
15 that you can and can't inquire about in
16 this litigation. So we will continue to
17 instruct the witness not to answer when
18 you ask specific questions about specific
19 activities related to products other than
20 Digitek.

21 BY MR. BLIZZARD:

22 Q Okay. Did you work on hydroxyzine?

23 MR. ANDERTON: Objection. I'm
24 going to instruct the witness not to
1 answer.

2 BY MR. BLIZZARD:

3 Q Did you work on oxycodone?

4 MR. ANDERTON: Objection. I'm
5 going to instruct the witness not to
6 answer.

7 BY MR. BLIZZARD:

8 Q Did you work on phentermine?

9 MR. ANDERTON: Objection. I

10 instruct the witness not to answer.

11 BY MR. BLIZZARD:

12 Q Did you -- would you work on

13 glyburide?

14 MR. ANDERTON: Objection. I

15 instruct the witness not to answer.

Page 126

2 Q Was it ever brought to your

3 attention that it wasn't followed from time to

4 time by people who were working in the lab?

5 MR. ANDERTON: Objection. I

6 instruct the witness to answer only with

7 respect to Digitek.

Anil Patel

October 27, 2009

Page 43

8 Q Did you ever become aware that the

9 good manufacturing procedures in the lab at

10 Little Falls were being routinely violated?

11 MR. ANDERTON: Objection.

12 You may answer.

13 And I instruct the witness to

14 answer only with respect to Digitek, or

15 digoxin. Sorry.

Page 92/93

10 Q Can you give me a sense for your

11 time as you've been employed, from 1999 until

12 today, how often do out-of-specification

13 results occur?

14 MR. ANDERTON: Objection.

15 I'm going to instruct the

16 witness to answer only with respect to

17 digoxin.

18 MR. MILLER: I'm not asking for

19 any individual product here. I'm asking

20 for the -- I don't want to know product

21 names. I'm just looking for how often an

22 out-of-specification result occurs for a

23 lab analyst at the quality control

24 department.

1 MR. ANDERTON: I understand.

2 My objection stands and my instruction
3 stands.
4 Please answer that question
5 only with respect to digoxin.

Paul Galea
December 9, 2009

Page 253

2 Q. And there was a voluntary
3 commitment to perform product assessments
4 and to requalify equipment, evaluate it
5 and, as needed, remediate and requalify
6 methods and perform new process and
7 cleaning validation studies prior to the
8 reintroduction of any product to the
9 market?
10 Do you see that?
11 A. Yes.
12 Q. On the last item, has that been
13 accomplished?
14 MR. ANDERTON: Objection.
15 I'm going to instruct you to answer
16 only with respect to Digitek.

Page 260/261/262

20 Has anybody communicated to you
21 about why they shut down the plant and recalled
22 all the products made at the plant?
23 MR. ANDERTON: Objection.
24 I'm going to instruct the witness
1 to answer only with respect to Digitek.
2 THE WITNESS: With respect to
3 Digitek, it was in view of the findings that the
4 FDA found.
5 BY MR. BLIZZARD:
6 Q. Well, they suspended operations at the
7 entire plant, didn't they?
8 A. Yes.
9 Q. Do you know why?
10 MR. ANDERTON: Objection.
11 THE WITNESS: I believe they wanted
12 to ensure that they could address the findings
13 from the FDA before resuming any manufacturing.
21 Q. Okay. Because of the findings
22 of the FDA, and the involvement in -- of

23 senior management in the discussion with
24 FDA, was it uncertain whether the drugs
1 being produced by the plant, any of them,
2 were in compliance with GMPs?
3 MR. ANDERTON: Objection.
4 I instruct the witness to answer
5 only with respect to Digitek.

Richard Dowling
December 16, 2009.

Page 164/165

19 Q Well, that's a little bit different.
20 Were you aware of blend uniformity problems
21 among any product that was being produced at
22 the Little Falls plant?
23 MR. ANDERTON: Objection.
24 I instruct the witness to
1 answer only with respect to Digitek.
2 THE WITNESS: I don't recall.

Page 273

14 Q Were there other batches other than
15 70924, to your recollection, sir, that had an
16 issue of unusual thickness in the packaging,
17 found in packaging?
18 MR. ANDERTON: Objection.
19 I instruct the witness to
20 answer only with respect to Digitek.

Swapnan Roychowdhury
December 15, 2009

Page 268

15 Q Did the FDA 483 investigations have
16 anything to do with the 100 products we
17 discussed the production line being stopped?
18 MR. ANDERTON: Objection. I
19 instruct the witness to answer only with
20 respect to Digitek.